| pubmed-article:2909866 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:2909866 | lifeskim:mentions | umls-concept:C0086418 | lld:lifeskim |
| pubmed-article:2909866 | lifeskim:mentions | umls-concept:C0229613 | lld:lifeskim |
| pubmed-article:2909866 | lifeskim:mentions | umls-concept:C0026882 | lld:lifeskim |
| pubmed-article:2909866 | lifeskim:mentions | umls-concept:C1154744 | lld:lifeskim |
| pubmed-article:2909866 | lifeskim:mentions | umls-concept:C1553039 | lld:lifeskim |
| pubmed-article:2909866 | lifeskim:mentions | umls-concept:C0443252 | lld:lifeskim |
| pubmed-article:2909866 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:2909866 | pubmed:dateCreated | 1989-2-8 | lld:pubmed |
| pubmed-article:2909866 | pubmed:abstractText | We have studied the mutagenic effects of benzo[a]pyrene (BP) administered in a long-term, low-dose fashion to metabolically competent human lymphoblastoid cells. A continuous dose as low as 0.02 microM for 20 days produced a significant increase in mutant fraction at the 6TG-resistance (HGPRT) locus. The slope of the mutant fraction over time in the 0.02 microM BP-treated culture was twice that observed in the untreated concurrent control; 0.02 microM therefore represents the doubling dose of BP for gene mutation in this cell line. For higher doses of 0.1, 0.5 or 1 microM BP, the rate (or efficiency) of induced mutation was considerably higher for the first 5 or 6 days of exposure than for the last 14-15. This did not appear to be due to a growth disadvantage against early-arising mutants. Comparison to previously published data in the same cell system (Crespi and Thilly, 1984) revealed that the long-term , low-dose protocol (0-1 microM for up to 20 days) was significantly more efficient at inducing mutations than a short-term, high-dose protocol (0-10 microM for 1 day). | lld:pubmed |
| pubmed-article:2909866 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2909866 | pubmed:language | eng | lld:pubmed |
| pubmed-article:2909866 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2909866 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:2909866 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2909866 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2909866 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:2909866 | pubmed:month | Jan | lld:pubmed |
| pubmed-article:2909866 | pubmed:issn | 0027-5107 | lld:pubmed |
| pubmed-article:2909866 | pubmed:author | pubmed-author:ThillyW GWG | lld:pubmed |
| pubmed-article:2909866 | pubmed:author | pubmed-author:LiberH LHL | lld:pubmed |
| pubmed-article:2909866 | pubmed:author | pubmed-author:DanheiserS... | lld:pubmed |
| pubmed-article:2909866 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:2909866 | pubmed:volume | 210 | lld:pubmed |
| pubmed-article:2909866 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:2909866 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:2909866 | pubmed:pagination | 143-7 | lld:pubmed |
| pubmed-article:2909866 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:2909866 | pubmed:meshHeading | pubmed-meshheading:2909866-... | lld:pubmed |
| pubmed-article:2909866 | pubmed:meshHeading | pubmed-meshheading:2909866-... | lld:pubmed |
| pubmed-article:2909866 | pubmed:meshHeading | pubmed-meshheading:2909866-... | lld:pubmed |
| pubmed-article:2909866 | pubmed:meshHeading | pubmed-meshheading:2909866-... | lld:pubmed |
| pubmed-article:2909866 | pubmed:meshHeading | pubmed-meshheading:2909866-... | lld:pubmed |
| pubmed-article:2909866 | pubmed:meshHeading | pubmed-meshheading:2909866-... | lld:pubmed |
| pubmed-article:2909866 | pubmed:meshHeading | pubmed-meshheading:2909866-... | lld:pubmed |
| pubmed-article:2909866 | pubmed:meshHeading | pubmed-meshheading:2909866-... | lld:pubmed |
| pubmed-article:2909866 | pubmed:meshHeading | pubmed-meshheading:2909866-... | lld:pubmed |
| pubmed-article:2909866 | pubmed:year | 1989 | lld:pubmed |
| pubmed-article:2909866 | pubmed:articleTitle | Long-term, low-dose benzo[a]pyrene-induced mutation in human lymphoblasts competent in xenobiotic metabolism. | lld:pubmed |
| pubmed-article:2909866 | pubmed:affiliation | Center for Environmental Health Sciences, Massachusetts Institute of Technology, Cambridge 02139. | lld:pubmed |
| pubmed-article:2909866 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:2909866 | pubmed:publicationType | In Vitro | lld:pubmed |
| pubmed-article:2909866 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:2909866 | pubmed:publicationType | Research Support, U.S. Gov't, Non-P.H.S. | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2909866 | lld:pubmed |
